Cryo Cell International Inc: Form 10-Q for the period ended Aug 31, 2016
Filed with the SEC on Oct 17, 2016 and accepted by EDGAR at Oct 17, 2016, 21:28 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2016-06-01 to 2016-08-31 | $6.3m | us-gaap:Revenues |
| Revenue | 9 months2015-12-01 to 2016-08-31 | $17.3m | us-gaap:Revenues |
| Cost of revenue | 3 months2016-06-01 to 2016-08-31 | $1.6m | us-gaap:CostOfServices |
| Cost of revenue | 9 months2015-12-01 to 2016-08-31 | $4.3m | us-gaap:CostOfServices |
| Research and development | 3 months2016-06-01 to 2016-08-31 | $13.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2015-12-01 to 2016-08-31 | $34.5k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2016-06-01 to 2016-08-31 | $3.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2015-12-01 to 2016-08-31 | $10.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2016-06-01 to 2016-08-31 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2015-12-01 to 2016-08-31 | −$23.3k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2016-06-01 to 2016-08-31 | $199.4k | us-gaap:InterestExpense |
| Interest expense | 9 months2015-12-01 to 2016-08-31 | $804.2k | us-gaap:InterestExpense |
| Income tax | 3 months2016-06-01 to 2016-08-31 | −$898.8k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2015-12-01 to 2016-08-31 | −$697.1k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-06-01 to 2016-08-31 | −$2.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2015-12-01 to 2016-08-31 | −$2.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-06-01 to 2016-08-31 | −$0.35 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2015-12-01 to 2016-08-31 | −$0.25 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-06-01 to 2016-08-31 | −$0.35 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2015-12-01 to 2016-08-31 | −$0.25 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-06-01 to 2016-08-31 | 7,583,771 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2015-12-01 to 2016-08-31 | 8,546,110 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2015-12-01 to 2016-08-31 | $2.4m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months2015-12-01 to 2016-08-31 | $298.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2015-12-01 to 2016-08-31 | $10.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2016-08-31 | $2.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-08-31 | $10.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-08-31 | $17.5m | us-gaap:Assets |
| Current liabilities | At period end2016-08-31 | $12.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-08-31 | $34.6m | us-gaap:Liabilities |
| Long-term debt | At period end2016-08-31 | $1.4m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2016-08-31 | −$17.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-16-739879. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.